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Aims. We investigated the relationship between circulating amino acid levels and obesity; to what extent weight loss followed by
weight maintenance can correct amino acid abnormalities; and whether amino acids are related to weight loss. Methods. Amino
acids associated with waist circumference (WC) and BMI were studied in 804 participants from the Malmö Diet and Cancer
Cardiovascular Cohort (MDC-CC). Changes in amino acid levels were analyzed after weight loss and weight maintenance in 12
obese subjects and evaluated in a replication cohort (n = 83). Results. Out of the eight identiﬁed BMI-associated amino acids
from the MDC-CC, alanine, isoleucine, tyrosine, phenylalanine, and glutamate decreased after weight loss, while asparagine
increased after weight maintenance. These changes were validated in the replication cohort. Scores that were constructed based
on obesity-associated amino acids and known risk factors decreased in the ≥10% weight loss group with an associated change in
BMI (R2 = 0 16–0 22, p < 0 002), whereas the scores increased in the <10% weight loss group (p < 0 0004). Conclusions. Weight
loss followed by weight maintenance leads to diﬀerential changes in amino acid levels associated with obesity. Treatment
modiﬁable scores based on epidemiological and interventional data may be used to evaluate the potential metabolic beneﬁt of
weight loss.
1. Introduction
Pathophysiological changes developing in the presence of
obesity are often present long before the chronic hyper-
glycemia of type 2 diabetes (T2D) is manifest [1].
During these early stages, T2D can often be prevented
by lifestyle changes, including weight loss and increased
physical activity [2, 3]. More substantial weight loss
achieved by bariatric surgery may even lead to remission
of manifest T2D [4–6]. However, bariatric surgery is
neither suitable nor available for all patients who may
beneﬁt from it. Therefore, early detection of subjects at
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risk and eligible for less invasive preventive measures is
of great importance.
Predictors such as heritability, body mass index (BMI),
waist circumference (WC), and fasting plasma glucose are
helpful in gauging T2D risk, and in the recent years, meta-
bolic proﬁling of phenotypic abnormalities have provided
additional information [7–10]. Several circulating metabo-
lites, which may reﬂect the biochemical environment of an
individual, have shown altered levels in metabolic disorders.
Notably, the aromatic and branched-chain amino acids
(BCAAs) have been associated with, as well as predict, the
development of insulin resistance [11, 12]. They have also
been associated with the risk of developing T2D, and a com-
bination of isoleucine, tyrosine, and phenylalanine was a
particularly strong predictor of incident T2D [13, 14]. We
extended this ﬁnding by demonstrating that the same amino
acids (AAs) are associated with risk of future cardiovascular
disease (CVD) even after adjusting for insulin resistance
and T2D [15].
Recently, there has been an increased focus on metabolite
levels following weight loss intervention in order to resolve
which biological factors change in response to reduced
weight and improved health proﬁle [16–24]. For instance,
BCAAs were found to predict improvement in insulin resis-
tance with moderate weight loss [19]. However, the potential
weight loss-associated improvements of the BCAAs have
been inconsistent and further analysis is required [18–24].
In this report, we investigated the association between
plasma AA levels and measures of obesity, WC, and BMI in
a large population-based study to identify AAs indepen-
dently associated with obesity. We then proﬁled AA changes
during a weight loss intervention followed by a period of
weight maintenance, allowing detection of when speciﬁc
weight loss-related changes may occur for obesity-
associated AAs. Scores were constructed that potentially
can be used as predictors of the beneﬁt of pursuing a weight
loss and weight maintenance program, that is, identifying
subjects that are not only at risk because of obesity but also
likely to beneﬁt from weight loss. Finally, we included a rep-
lication cohort to further evaluate weight loss-induced
changes in AA levels and risk scores.
2. Methods
2.1. Study Cohorts
2.1.1. The Malmö Diet and Cancer Cardiovascular Cohort
(MDC-CC). The Malmö Diet and Cancer (MDC) study is a
population-based, prospective epidemiologic cohort of
28,449 persons enrolled between 1991 and 1996 in Southern
Sweden. From this cohort, 6103 persons were randomly
selected to participate in the MDC Cardiovascular Cohort
(MDC-CC), which was originally designed to investigate
the epidemiology of carotid artery disease [25, 26]. The study
subjects with metabolomics data were derived from a nested
incident CVD case-control study (n = 506) with subjects
matched for gender, age, and the Framingham risk score [27]
and a nested incident diabetes case-control study (n = 326)
originating from the MDC-CC as described previously [15].
Subjects who had participated in both studies above were
excluded (n = 27), leaving 805 individuals, 804 out of
whom had complete data on all covariates and were used
in this report (Table 1).
2.1.2. Weight Loss and Weight Maintenance (WLWM)
Cohort. To evaluate metabolite levels modiﬁable with a con-
trolled weight loss intervention, 12 obese individuals referred
to the Obesity Unit at Skåne University Hospital, Malmö,
Sweden, and participated in a WLWM program. The inter-
vention study has been described in detail previously
(Table 1) and is independent of the MDC-CC study [7, 14,
28]. Brieﬂy, the participants were prescribed a low-calorie
diet (1200 kcal/day) for approximately three months
(101± 26 days) followed by a six-month weight maintenance
program (167± 37 days) consisting of group sessions with
exercise and diet counseling [28]. Fasting blood samples were
drawn at three time points: at baseline, after weight loss, and
after weight maintenance. Subjects were weight stable at
baseline and weight maintenance [28]. All subjects met the
inclusion criteria of at least 10% weight loss and maintained
this weight (±5%) during the weight maintenance phase.
2.1.3. Replication Cohort. In order to evaluate ﬁndings from
the WLWM cohort, a replication cohort was included
consisting of a larger group of 83 obese individuals that par-
ticipated in nonsurgical weight loss programs at the Depart-
ment of Endocrinology, Skåne University Hospital, Malmö,
Sweden. The programs were based on behavioral therapy
(individually or in groups) and whenever possible proceeded
by a prolonged period with a low-calorie diet as previously
described [7, 28, 29]. Participants were included based on
complete data on amino acids, both before and after weight
loss treatment, as well as information regarding hypertension
and T2D status. Anthropometric data are presented in
Table 1. There was no overlap of subjects participating either
in both the WLWM and the replication cohort or in the
MDC-CC study. The study protocols were approved by the
Institutional Review Boards of Lund University, Sweden.
All participants provided written informed consent. Neither
the WLWM nor the replication cohorts were registered as
clinical trials as recruitment for these studies started in
2004, when registration was not required.
2.2. Clinical Assessment. Blood pressure was obtained after 10
minutes of rest in supine position. Hypertension was deﬁned
as systolic blood pressure (SBP) ≥140mmHg or diastolic
blood pressure (DBP) ≥90mmHg, or use of antihypertensive
treatment (AHT). Diabetes was deﬁned as fasting whole
blood glucose > 6 0mmol/L, a self-reported physician diag-
nosis of diabetes, or use of antidiabetic medication. Fasting
insulin, triglycerides, and total- and HDL cholesterol were
measured according to the standard procedures at the
Department of Clinical Chemistry, Skåne University Hospi-
tal, Malmö, Sweden. LDL cholesterol was calculated using
the Friedewald formula. HOMA-IR was used as an estimate
of insulin resistance [30].
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2.3. Metabolite Proﬁling. Plasma samples were collected at
baseline exam in the MDC-CC and metabolites were proﬁled
using liquid chromatography-tandem mass spectrometry
(LC-MS) as described in detail previously [14, 15, 27]. For
the WLWM cohort, metabolite proﬁling was performed on
three aliquots of 100μL plasma from each subject, and for
the replication cohort, 40μL serum was analyzed. Metabolite
separation and detection for both WLWM and replication
cohorts were performed using gas chromatography-mass
spectrometry (GC-MS) as previously described [7, 31]. In
the WLWM cohort, a total of 108 plasma samples were run
in randomized order. In the replication cohort, a total of
168 samples were analyzed in two randomly assembled
batches. Isoleucine and leucine were detected as separate
peaks in the MDC-CC analysis and replication cohort,
and as one peak in the WLWM analysis, thus isoleucine
and leucine will be referred as isoleucine/leucine in the
WLWM cohort.
2.4. Data Analysis. The data analysis was comprised of three
cohort stages (Figure 1). First, we aimed to identify AAs
independently associated with continuous or categorical
measures of obesity in the MDC-CC database (WC and
BMI; abdominal obesity (WC> 102 cm for men; >88 cm for
women [32]) and general obesity (BMI > 30 kg/m2)), to cre-
ate AA proﬁle scores for obesity (OB), OB-WC and OB-
BMI, that included AAs positively or negatively associated
with WC and BMI, respectively, along with age, gender,
AHT, SBP, and T2D. Second, new scores were created using
the same set of variables minus those AAs that did not show
change towards levels that had been previously observed in
lean insulin-sensitive individuals [8, 32–34], which suggests
improvement as a result of the WLWM intervention,
WLWM-WC and WLWM-BMI. The OB scores assess the
total AA-associated burden of obesity, whereas the WLWM
scores assess the portion of this burden which may change
by a weight loss and weight maintenance program. Third,
we evaluated whether these scores were associated with
weight loss as well as validation of change in AA levels in
an independent replication cohort.
2.4.1. Amino Acid Levels Associated withWaist Circumference
and BMI. In the MDC-CC, all plasma AA levels were log
transformed and scaled to multiples of one standard devi-
ation (SD). The previously reported diabetes-predictive
amino acid (DM-AA) score, was modeled according to
the formula: z-score of log X1 + z-score of log X2 + z-score
of log X3 with Xj denoting the AAs, isoleucine, tyrosine,
Table 1: Baseline characteristics of the participants in the Malmö Diet and Cancer Cardiovascular Cohort (MDC-CC), the Weight Loss and
Weight Maintenance intervention study, and the replication cohort.
MDC-CC Weight Loss and Weight Maintenance intervention Replication cohort
At baseline After weight lossa After weight maintenanceb At baseline At follow-upc
N 804 12 12 12 83 83
Age (years) 59.2± 5.5 35.7± 12.3 35.8± 12.3 36.4± 12.3 44.5± 11.9 45.4± 11.9
Sex (% women) 51.3 75 75 75 67 67
Weight (kg) 77.8± 14.8 132.8± 23.2 110.7± 23.6f 106.4± 25.5g 123.5± 22.0 104.8± 23.1i
Weight loss (%) — — −17.1± 5.6 −20.1± 10.2 — −15.0± 11.0
BMI (kg/m2) 27.1± 4.5 44.2± 5.8 36.9± 6.6f 35.4± 7.3g 42.5± 5.8 36.1± 6.6i
Waist circumference (cm) 88.6± 13.8 130.6± 10.0d 112.5± 14.2f 107.7± 15.0g 125.6± 15.7 111.2± 17.7i
Fasting glucose (mmol/L) 5.4± 1.4 4.8± 0.6 4.6± 0.7 4.6± 0.3 6.2± 2.5 5.6± 1.7i
Fasting insulin (μU/mL) 9.5± 9.6 10.8± 6.1d 4.7± 3.7f 6.3± 4.6g 14.4± 8.2 9.6± 7.2i
HOMA-IR 2.4± 3.0 2.3± 1.3d 1.0± 0.9f 1.3± 1.0g 4.1± 3.1 2.6± 2.4i
HOMA-IR decrease (%) — — −58.6± 24.4 −49.4± 25.2 — −28.1± 55
LDL (mmol/L) 4.3± 1.0 3.1± 0.9 2.8± 0.5d 2.9± 0.9 3.1± 0.9 2.9± 0.9i
HDL (mmol/L) 1.3± 0.3 1.1± 0.4 1.0± 0.2d 1.3± 0.3h 1.1± 0.3 1.1± 0.3
Triglycerides (mmol/L) 1.5± 0.7 1.4± 0.8 0.8± 0.3d,f 0.8± 0.5g 1.5± 1.2 1.1± 0.7i
Diabetes (%) 7.2 0 0 0 19.3 19.3
Current smoker (%) 30.3 16.7 16.7 16.7 21.5∗ 21.5∗
SBP (mmHg) 147.4± 18.7 126.7± 16.5e 121.5± 9.2 117.5± 14.4 129± 14.8 122± 15.2i
AHT (%) 23.7 0 0 0 30.1 30.1
Hypertension (%) 77.1 0 0 0 49.4 41.0
a,b,c,eThe weight loss period with low-calorie diet lasted 101 ± 26 days; the weight maintenance period with counseling lasted 167 ± 37 days. Average time span
between baseline and follow-up in replication cohort was 345 ± 195 days. Data expressed as mean ± SD. dData missing from one person at that time. Data
missing from two persons at that time.
fp < 0 05 between baseline and weight loss (Weight Loss and Weight Maintenance intervention).
gp < 0 05 between baseline and weight maintenance (Weight Loss and Weight Maintenance intervention).
hp < 0 05 between weight loss weight maintenance (Weight Loss and Weight Maintenance intervention).
ip < 0 05 between baseline and follow-up (replication cohort).
∗Smoke status is lacking for 4 subjects.
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and phenylalanine [14, 15]. The score was then scaled to
multiples of one SD. Correlations with WC and BMI were
calculated from linear regression while adjusting for age,
sex, diabetes status, AHT, and SBT. Associations were
considered signiﬁcant at a two-tailed p < 0 003 (p < 0 05
Bonferroni corrected for the 18 measured AAs). The OB-WC
and OB-BMI scores were constructed from the AA levels
weighted by theβ-coeﬃcients calculated frombackward elim-
ination regression of all AAs which correlated toWC or BMI,
respectively, adjusted for age, sex, diabetes status, AHT, and
SBP. All calculations in theMDC-CCwere performed in SPSS
Windows (v. 20.0) or STATA (v. 12, StataCorp.).
2.4.2. Changed Amino Acid Levels during the Weight Loss and
Weight Maintenance Program. For the WLWM cohort, the
raw data pretreatment and peak identiﬁcation were per-
formed as described previously [31]. All modeling was
performed in SIMCA 13.0 (Umetrics, Umeå, Sweden),
using principal component analysis (PCA) [35] or orthog-
onal projections to latent structures discriminant analysis
(OPLS-DA) [36]. Prior to analysis, multiple peaks stem-
ming from the same metabolite were added. Score vector
from the ﬁrst principal component of noncentered PCA
model for isotope-labeled internal standards was used to
normalize the metabolite dataset [37]. Samples were
extracted and processed in triplicates so an average level
was calculated prior to further analysis. Finally, the metab-
olite dataset was combined with hormone, cholesterol, and
triglyceride levels to form the ﬁnal dataset of 59 measured
variables in 36 samples. Variables deviating from the
normal distribution were log transformed and all variables
were double centered and scaled to unit variance [38, 39].
Outliers were eliminated using a PCA model and Hotell-
ing’s t-test [40]. The metabolic regulation during weight
loss was studied by setting up an OPLS-DA model with
only the levels measured at baseline and weight loss. In
the same manner, a model was calculated for weight
maintenance, comparing the levels measured at weight loss
and weight maintenance, and for the whole course of the
program, comparing levels measured at baseline and
weight maintenance. In all models, noise was reduced by
limiting the number of latent components with cross-
validation [41, 42]. The proﬁle for each variable during
the weight loss and weight maintenance program was con-
structed from the loadings from each model.
The WLWM-WC and WLWM-BMI scores were
constructed similarly to the OB scores from the MDC-CC,
but only included β-coeﬃcients of AAs whose change, dur-
ing the weight loss and weight maintenance program, moved
towards levels that have previously been observed in lean
subjects (judged from baseline to weight maintenance). The
z-scores of the logarithmic values of each amino acid level
were used. For backward elimination, an exclusion thresh-
old of p < 0 100 was used. We also assessed whether the
risk for CVD and T2D, represented by the previously
presented DM-AA score [14, 15], could decrease by the
weight loss and weight maintenance intervention in an
analogous manner.
1
MDC-CC cohort
푁= 804
Identify amino acids
associated with BMI and
waist circumference in a
population-based cohort.
2
WLWM cohort
푁=12
Changes in amino acids were studied in
an obese cohort after diet-induced
weight loss and weight maintenance
loss and after weight maintenance.
limited to those modifiable with weight
OB score
First set of obesity scores
calculated based on훽-
estimates from amino acids
associated with BMI and
waist circumference and
related risk factors.
WLWM score
Second set of scores were
calculated based on the amino
acids from the OB score but
only including those amino
loss and weight maintenance.
acids modifiable with wieght
The WLWM score also
included related risk factors as
in the OB score.
3
Replication cohort
푁= 83
OB and WLWM scores, as well as amino acid levels, were
evaluated in an independent obesity cohort who
participated in a weight loss program.
Change in amino
acid levels
Weight loss-induced
change in amino acid
levels was evaluated in
subjects with≥10%
weight loss.
Figure 1: An overview of the study design. MDC-CC: Malmö Diet and Cancer Cardiovascular Cohort, OB: obesity, WLWM: weight loss
weight maintenance.
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Each score (OB-BMI, OB-WC, WLWM-BMI, and
WLWM-WC) was evaluated in the replication cohort. The
respective AAs were log transformed and standardized
before calculating the OB-BMI/WC, WLWM-BMI/WC,
and DM-AA scores according to the formulas developed or
previously reported. T2D cases (n = 17) were excluded prior
to calculating the DM-AA score in replication cohort.
3. Results
3.1. Amino Acid Levels and Their Association to Measures of
Obesity. Univariate linear regression analysis of data from
the MDC-CC showed that the plasma levels of 12 out of 18
identiﬁed AAs were associated with WC after adjusting for
sex and age (Table 2). Adjustment for T2D and CVD risk fac-
tors (SBP and AHT) reduced the number of associated AAs
to ten, six showing a positive and four showing a negative
correlation. With the exception of leucine, which showed
no correlation to BMI in the fully adjusted model, the same
AAs were associated with BMI as with WC (Table 2).
The DM-AA score also showed a strong positive correla-
tion with both WC and BMI. A signiﬁcant gender eﬀect
was observed for asparagine (BMI: β = −0 743, p = 0 017,
WC: β = −1 577, p = 0 047), glutamate (BMI: β = 0 807,
p = 0 011, WC: β = 2 514, p = 0 002), proline (BMI:
β = 1 091, p = 0 001, WC: β = 2 853, p = 0 001), and valine
(only WC: β = 1 883, p = 0 025) for their association with
obesity in MDC-CC. Next, we tested the association between
AAs or the DM-AA score, and categorical measures of obe-
sity such as abdominal obesity based on WC, and general
obesity based on BMI (Supplementary Figure 1 available
online at https://doi.org/10.1155/2017/6490473). The same
AAs were signiﬁcantly associated with these measures; in
both cases, their odds ratios were similar, and levels of these
AAs had also been associated with both WC and BMI in the
preceding analysis.
To identify AAs that were independently associated with
WC and BMI, we performed backward elimination regres-
sion with sex, age, SBP, AHT, and T2D status as covariates
(Table 3). WithWC as response variable, isoleucine and phe-
nylalanine were eliminated, and with BMI as response
variable, glutamate and phenylalanine were eliminated. The
coeﬃcient of determination for the independent association
of AAs with WC was higher than for BMI (R2 = 0 54 and
R2 = 0 31, resp.). From the associated AAs, we constructed
two scores, OB-WC and OB-BMI, according to the following
formulas signifying the relationship between obesity and
AA levels:
OB−WC= 108 + 2 39 Ala − 4 01 Asn + 0 96 Glu
− 1 41 Gly + 2 96 Tyr + 1 21 Val
− 13 4 sex − 0 12 age + 0 05 SBP
+ 2 27 AHT + 4 26 T2D ,
OB− BMI = 26 8 + 0 92 Ala − 1 40 Asn − 0 58 Gly
− 0 61 Ile + 1 03 Tyr + 1 01 Val
+ 0 12 sex − 0 061 age + 0 02 SBP
+ 0 98 AHT + 1 50 T2D
1
Table 2: Amino acids associated with waist circumference and BMI in the Malmö Diet and Cancer Cardiovascular Cohort.
Amino acids
Model 1
(adjusted for age and gender)
Model 2
(adjusted for age, gender, SBP, AHT, and T2D status)
βWC (SE) p βBMI (SE) p βWC (SE) p βBMI (SE) p
Alanine 3.359 (0.393) <0.001 1.215 (0.153) <0.001 3.337 (0.377) <0.001 1.197 (0.148) <0.001
Arginine −0.452 (0.408) 0.268 −0.241 (0.158) 0.128 −0.407 (0.392) 0.299 −0.220 (0.152) 0.149
Asparagine −2.800 (0.397) <0.001 −0.996 (0.155) <0.001 −2.137 (0.391) <0.001 −0.822 (0.153) <0.001
Glutamate 2.642 (0.401) <0.001 0.791 (0.157) <0.001 2.125 (0.393) <0.001 0.591 (0.154) <0.001
Glutamine −2.029 (0.409) <0.001 −0.780 (0.159) <0.001 −1.613 (0.398) <0.001 −0.632 (0.155) <0.001
Glycine −3.348 (0.413) <0.001 −1.286 (0.160) <0.001 −2.940 (0.403) <0.001 −1.138 (0.157) <0.001
Isoleucine 2.746 (0.448) <0.001 0.849 (0.175) <0.001 2.054 (0.448) <0.001 0.594 (0.175) 0.001
Leucine 1.377 (0.447) 0.002 0.431 (0.174) 0.013 0.681 (0.443) 0.124 0.180 (0.172) 0.295
Lysine 0.615 (0.408) 0.133 0.231(0.158) 0.144 0.450 (0.393) 0.252 0.173 (0.153) 0.259
Methionine 0.670 (0.427) 0.117 0.191 (0.166) 0.249 0.632 (0.410) 0.124 0.168 (0.160) 0.293
Ornithine −1.184 (0.409) 0.004 −0.467 (0.159) 0.003 −1.245 (0.393) 0.002 −0.482 (0.153) 0.002
Phenylalanine 2.726 (0.408) <0.001 1.006 (0.159) <0.001 2.584 (0.392) <0.001 0.951 (0.153) <0.001
Proline 1.081 (0.414) 0.009 0.405 (0.161) 0.012 1.128 (0.397) 0.005 0.422 (0.155) 0.007
Serine −1.566 (0.411) <0.001 −0.599 (0.160) <0.001 −0.969 (0.404) 0.017 −0.382 (0.157) 0.015
Threonine −1.512 (0.406) <0.001 −0.541 (0.158) 0.001 −1.106 (0.396) 0.005 −0.396 (0.154) 0.01
Tryptophan 0.434 (0.428) 0.311 0.097 (0.166) 0.558 0.330 (0.411) 0.423 0.052 (0.160) 0.743
Tyrosine 3.835 (0.387) <0.001 1.367 (0.152) <0.001 3.586 (0.376) <0.001 1.261 (0.148) <0.001
Valine 3.021 (0.418) <0.001 1.085 (0.163) <0.001 2.408 (0.418) <0.001 0.863 (0.163) <0.001
DM-AA score 4.091 (0.406) <0.001 1.425 (0.159) <0.001 3.648 (0.170) <0.001 1.256 (0.156) <0.001
Models 1 and 2: linear regression analysis to test amino acids association with waist circumference and BMI; β: standardized regression coeﬃcient;
SE: standard error.
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3.2. The Eﬀect of Weight Loss Followed by Weight
Maintenance on Amino Acids and the Obesity Scores. All
participants in the controlled weight loss and weight
maintenance program met the inclusion criteria of ≥10%
weight loss with an average weight loss of 20.1± 10.2%
(mean± SD) during the weight loss phase and maintained
the reduced weight (±3.9%) during the six-month weight
maintenance phase (Table 1).
The PCA of the complete dataset from the weight loss
and weight maintenance program showed three clusters,
reﬂecting baseline, weight loss, and weight maintenance, sug-
gesting that there were diﬀerences in metabolite levels
between the time points (Supplementary Figure 2A). To dis-
criminate between baseline, weight loss, and weight mainte-
nance, an OPLS-DA model was created. The resulting score
plot revealed a clear separation between the diﬀerent time
points, conﬁrming that there were diﬀerences in metabolite
levels between baseline, weight loss, and weight maintenance
(Supplementary Figure 2B). Most AA levels (78%) changed
during the weight loss intervention and 86% out of those,
67% of the 18 identiﬁed AAs, remained changed after weight
maintenance. We grouped the AAs and the DM-AA, OB-
BMI, and OB-WC scores according to their weight loss-
and weight maintenance-change pattern into ﬁve distinct
groups (Table 4). Three change patterns towards levels found
in normal weight subjects were found for AA levels that
showed long-term changes: (i) decrease during weight loss
and sustained levels during weight maintenance, glutamate,
isoleucine/leucine, serine, and the OB-WC score; (ii)
decrease during weight loss followed by partial increase
during weight maintenance, alanine, aspartate, aromatic
AAs, tryptophan, and the DM-AA and OB-BMI scores; and
(iii) no change during weight loss followed by an increase
during weight maintenance, asparagine, glutamine, and
methionine [8–10, 32–34, 43]. Absence of long-term changes
was found for seven AAs, including glycine and the BCAA
valine (Table 4).
We then performed a backward elimination regression
using only the AAs, whose levels either increased or decreased
as a result of the whole weight loss and weight maintenance
program, that is, the modiﬁable part of the original OB
scores, to construct weight loss and weight maintenance
scores (Table 3):
WLWM−WC= 112 + 2 56 Ala − 4 52 Asn + 1 04 Glu
+ 3 56 Tyr − 14 8 sex − 0 15 age
+ 0 05 SBP + 2 48 AHT + 5 27 T2D ,
WLWM− BMI = 27 8 + 0 93 Ala − 1 64 Asn + 0 16 Ile
+ 1 28 Tyr − 0 08 sex − 0 08 age
+ 0 02 SBP + 1 04 AHT + 1 71 T2D
2
As expected, the weight loss and weight maintenance
scores decreased during weight loss and sustained decreased
during the weight maintenance phase (Table 4).
3.3. Evaluation of Weight Loss-Induced Amino Acid Changes
and Scores. In order to further evaluate AA changes after
weight loss treatment, we included a replication cohort with
subjects that participated in a similar weight loss treatment
program as the WLWM cohort except less controlled. This
meant fewer clinical visits, not meeting the criterion of at
Table 3: Backward elimination of amino acids associated with obesity traits in the Malmö Diet and Cancer Cardiovascular Cohort and
limited to amino acids which improved with the Weight Loss and Weight Maintenance program.
Amino acids
Model 1
(AAs associated with obesity traits in MDC-CC)
Model 2
(improved AAs after WLWM intervention)
βWC p βBMI p βWC p βBMI p
Alanine 2.39 <0.001 0.92 <0.001 2.56 <0.001 0.93 <0.001
Asparagine −4.01 <0.001 −1.40 <0.001 −4.52 <0.001 −1.64 <0.001
Glutamate 0.96 0.008 — 0.131 1.04 0.003 — —
Glycine −1.41 <0.001 −0.58 <0.001 — — — —
Isoleucine — 0.36 −0.61 0.034 — 0.166 0.16 0.369
Phenylalanine — 0.44 — 0.335 — 0.201 — —
Tyrosine 2.96 <0.001 1.03 <0.001 3.56 <0.001 1.28 <0.001
Valine 1.21 0.005 1.01 <0.001 — — — —
Sex −13.4 <0.001 0.12 0.714 −14.8 <0.001 −0.08 0.794
Age −0.12 0.068 −0.06 0.014 −0.15 0.017 −0.08 0.002
SBP 0.05 0.017 0.02 0.002 0.05 0.015 0.02 0.002
AHT 2.27 0.005 0.98 0.003 2.48 0.003 1.04 0.002
T2D status 4.26 0.002 1.50 0.007 5.27 <0.001 1.71 0.003
Model 1: amino acids with independent association with waist circumference to abdominal obesity and BMI to obesity, respectively. Regression coeﬃcients
from the backward elimination of amino acids associated with waist circumference and BMI in the Malmö Diet and Cancer Cardiovascular Cohort
(R2WC = 0.54 and R
2
BMI = 0.31 for Model 1). Model 2: amino acids that improve with the Weight Loss and Weight Maintenance program (i.e., excluding
glycine and valine based from Table 3), with independent association with waist circumference and abdominal obesity and BMI and obesity (R2WC = 0.53
and R2BMI = 0.28 for Model 2). Covariates; age, sex, SBP, AHT, and T2D status.
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least 10% weight loss, and sample collection at the visit before
and after attending the weight loss program only. Thus, par-
ticipants in the WLWM cohort were analyzed at baseline,
immediately after weight loss, and after a weight stability
phase, whereas the replication cohort was analyzed at base-
line and after 345± 195 days, that is, baseline and weight
maintenance phases in WLWM were comparable to baseline
and follow-up in the replication cohort. For subjects with
≥10% weight loss (n = 53), an increase of 5–24% was
observed for glutamine, asparagine, glycine, and serine and
a decrease of 6–14% was observed for ornithine, cysteine,
lysine, glutamate, alanine, proline, aspartate, and the aro-
matic AAs and BCAAs (Figure 2). Unchanged levels were
found for threonine, histidine, arginine, and tryptophan. In
total, 17 AAs were identiﬁed both in the WLWM and the
replication cohort: the change from baseline to weight
maintenance/follow-up could be validated for glutamine,
asparagine, phenylalanine, leucine, glutamate, alanine, tyro-
sine, isoleucine, aspartate, and threonine.
Overall, evaluation of the obesity scores in the replication
cohort (n = 83) showed no signiﬁcant change from baseline
to follow-up (Supplementary Table 1). Although, the regres-
sion of change in BMI on change in score level was strongly
signiﬁcant for each score (Supplementary Figure 3A–D).
Baseline score levels were not associated with change in
BMI from baseline to follow-up, and the scores were not dif-
ferent in those with ≥10% compared to <10% weight loss.
When regarding those with ≥ or <10% weight loss separately,
we found that the OB and WLWM scores decreased signiﬁ-
cantly in those with ≥10% weight loss (p < 0 003), whereas
signiﬁcant increases were seen in those with <10% weight
loss (p < 0 0004). In addition, the weight loss-induced
changes in both scores (OB and WLWM) were associated
with change in BMI in those with ≥10% weight loss (R2 for
OB-WC=0.22, WLWM-WC=0.17, OB-BMI=0.19, and
WLWM-BMI=0.16; p < 0 002), but not in the <10% weight
loss group (data not shown). The change in scores was highly
signiﬁcantly diﬀerent (p < 2e10−6) between the two weight
loss groups (≥ or <10% weight loss).
Participants with T2D were excluded in the analysis of
the DM-AA score (whole cohort: n = 67, ≥10% weight loss:
n = 44, <10% weight loss: n = 23). The DM-AA score
decreased from baseline to follow-up in the group with
≥10% weight loss (p = 0 04), and increased in the <10%
weight loss group (p = 0 04). The DM-AA scores in the two
weight loss groups (≥ or <10%) were diﬀerent at follow-up
(p = 0 002) as was the change in DM-AA score from baseline
to follow-up (p = 0 009), but not at baseline. This is further
illustrated in scatter plots depicting change in BMI against
change in DM-AA score using all nondiabetic participants
(Supplementary Figure 3 E). At baseline, there was no corre-
lation between BMI and DM-AA score, but at follow-up, and
especially the change from baseline to follow-up, these were
correlated (R2 = 0 16, p = 0 0006).
4. Discussion
Altered circulating AA levels have been observed inmetabolic
disorders, like obesity, T2D, and other insulin-resistant states
since many years and recent reports have supported these
ﬁndings [7–14, 19, 33, 44]. In the present study, we found a
panel of eight AAs: alanine, asparagine, glutamate, glycine,
phenylalanine, tyrosine, and the BCAAs isoleucine and
valine, to be independently associated with obesity after
adjusting for sex, age, SBP, AHT, and T2D. We included a
small cohort of subjects participating in a weight loss and
weight maintenance program showing changes towards
levels found in normal weight subjects (by either increased
or decreased plasma levels) in twelve AAs. To further validate
the changes observed, or lack of change after the weight loss
program, we included a replication cohort, where changes in
10 of the 17 AAs that could be compared were replicated.
Findings concerning these AAs and metabolic disease are
becoming increasingly robust, but the underlying mecha-
nisms remain largely elusive.
Previous studies using metabolomics to analyze AAs
levels have reported elevated levels of BCAAs in obese indi-
viduals (both with and without T2D) and in lean individuals
Table 4: Amino acid and amino acid score proﬁles during the
Weight Loss and Weight Maintenance program.
Proﬁle
Amino acids
and scores
Uncorrected predictive loadingsa
Weight
loss
Weight
maintenance
Whole
course
Asparagine −0.042 0.190 0.108
Glutamine −0.029 0.151 0.089
Methionine −0.012 0.170 0.140
Prolineb −0.077 0.161 0.050
Lysine −0.095 0.144 0.062
Valine −0.170 0.160 −0.087
Alanine −0.189 0.188 −0.150
Aspartate −0.214 0.111 −0.233
Tyrosine −0.177 0.201 −0.077
Phenylalanine −0.201 0.205 −0.107
Tryptophan −0.191 0.132 −0.130
DM-AA −0.196 0.189 −0.167
OB-BMI −0.210 0.111 −0.231
β-alanine −0.049 −0.032 −0.079
Cysteine −0.045 0.008 −0.048
Glycine 0.031 0.045 0.062
Threonine −0.041 0.083 0.018
Glutamate −0.195 −0.053 −0.271
Isoleucine/
leucine
−0.157 0.046 −0.191
WLWM-WC −0.208 0.048 −0.247
WLWM-BMI −0.198 0.062 −0.229
OB-WC −0.216 0.072 −0.253
Serine −0.229 0.063 −0.279
aLoadings obtained from multivariate data analysis and values in bold face
indicate a signiﬁcant change. bThe proﬁle for proline is not signiﬁcance
since the increase over the whole course is not signiﬁcance. The proﬁle for
each metabolite describes the change in metabolite levels between the three
time points: baseline, after weight loss and after weight maintenance. Each
time point is represented by a dot.
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with T2D, compared to the levels found in lean healthy sub-
jects [8]. While the biological mechanism behind this is
unclear, several reports have observed that metabolic imbal-
ance due to constant energy overload alters not only glucose
levels but also AA and fatty acid metabolism in peripheral tis-
sues [45, 46]. Speciﬁcally, it has been suggested that elevated
circulating BCAAs may be due to a deﬁciency of the BCAA-
catabolizing enzymes in the adipose tissue of obese subjects
[47–49]. Here, we investigated the associations between 18
amino acids and diﬀerent measures of obesity and found a
positive association for levels of alanine, glutamate, isoleu-
cine, phenylalanine, tyrosine, and valine and a negative asso-
ciation for those of asparagine and glycine (adjusting for sex,
age, SBP, AHT, and T2D). Only ﬁve AAs, arginine, lysine,
methionine, proline, and tryptophan, showed no association
in any of the models tested. The association between AA
levels and obesity appears to be very robust, and we conﬁrm
the positive associations of alanine, glutamate, isoleucine,
phenylalanine, tyrosine, and valine to obesity previously
reported [9, 10, 32, 33]. Interestingly, leucine showed associ-
ation toWC and BMI when adjusted for sex and age only, but
the association was lost with additional adjustment for
cardiovascular risk factors and T2D status. This may indicate
a stronger association to cardiovascular risk factors and
T2D than to obesity, as compared to the other two
BCAAs, isoleucine, and valine. The inverse association of
glycine and asparagine observed in this study conﬁrms
previous ﬁndings [32, 33, 50].
In this report, we aimed to identify AAs that are associ-
ated with obesity and to identify which AAs that change with
sustained weight loss towards levels found in healthy subjects
[8, 9, 32–34]. In order to do this, we ﬁrst examined AA
changes in a controlled weight loss and weight maintenance
group. The changes in AA levels were then analyzed in a rep-
lication cohort. Levels of several AAs associated with insulin
resistance have been found to change by either decreased or
increased levels towards levels found in subjects with normal
weight after weight loss, but few studies have included data
on long-term eﬀects [16, 18, 19, 21, 22]. While metabolite
levels at baseline can predict future outcome of obesity-
related metabolic disorders [12, 14, 15], multiple measure-
ments of metabolite levels may be necessary to evaluate
change in metabolic risk over time. Therefore, we also inves-
tigated which metabolite levels change with a weight loss and
weight maintenance program, metabolites that return to
baseline levels after weight maintenance, and metabolites
that appear to be unaﬀected although associated by obesity.
For instance, we found a decrease in BCAA levels during
weight loss, parallel to the improvement in insulin resistance,
as judged by HOMA-IR, and of triglyceride levels, which is in
agreement with previous studies, and as validated in the rep-
lication cohort [19, 23]. However, whereas the decrease in
isoleucine and leucine levels was sustained after weight main-
tenance, valine levels returned to baseline. Previous studies
both conﬁrm [18, 19, 21, 23] and contradict the observation
[20, 21, 24] of decreased isoleucine and leucine levels below
baseline levels after weight loss and weight maintenance.
Here, the decrease in valine remained after sustained weight
loss in our replication cohort. Diﬀerences in the amount of
weight loss, cohort size, or the observation times may
account for these diﬀerences between studies.
We also conﬁrm that weight loss induces reductions of
alanine, glutamate, phenylalanine and tyrosine levels in both
the WLWM and replication cohort [18, 24], and show that
these levels remain reduced after weight maintenance. By
contrast, a recent study by Tochikubo et al. reported that
unchanged levels of these AAs after weight loss were
observed in both female and male subjects [23]. Since they
applied a weight loss limit of 3%, this may indicate that more
profound weight loss is required to observe a decrease of
these amino acids. Asparagine provides an interesting exam-
ple as its level is strongly inversely associated with both WC
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Figure 2: Change in amino acid levels after weight loss treatment in the replication cohort. Percentage increase (dark grey), decrease (white),
and unchanged levels (striped) from the baseline to follow-up in the replication cohort are illustrated for those with ≥10% weight loss (n = 53).
Each bar represents the change at follow-up from baseline, which was set at 100%. ∗p < 0 05, ¥signiﬁcant after Bonferroni correction.
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and BMI and showed no response to weight loss but
increased during weight maintenance in the WLWM cohort.
Asparagine shares this change pattern with HDL cholesterol,
thus representing a proﬁle of late change after a weight loss
and weight maintenance program, which is paralleled by
the late appearance of improvement of glucose tolerance
[7]. The increase in levels of asparagine after sustained weight
loss was further validated in the replication cohort. Glycine,
on the other hand, which was also strongly inversely associ-
ated with obesity, was not signiﬁcantly aﬀected during any
part of the weight loss and weight maintenance program,
which has also been observed in other weight loss studies
[18, 21]. On the contrary, in the larger replication cohort, gly-
cine increased after weight loss, which is expected compared
to healthy individuals [8, 33]. In addition, cysteine has previ-
ously been associated with BMI, although since this AA was
not identiﬁed in the MDC-CC, we could not test the associa-
tion in this report, and the levels of cysteine did not respond
to the intervention in the WLWM cohort [51]. Nevertheless,
cysteine levels decreased in the larger replication cohort and
further investigation on cysteine is encouraged. Variables
including extent of weight loss, duration, pathogenesis,
cohort size, and type of intervention could explain inconsis-
tent changes in some AA levels. Furthermore, additional fac-
tors that potentially inﬂuence diﬀerences in AA levels
independently of obesity include insulin resistance, adipose
tissue distribution, and/or release of metabolites from the
gut microbiota into the circulation [48, 52, 53].
For the purpose of patient risk-beneﬁt assessment, we
created diﬀerent scores including classical risk factors (age,
sex, AHT, SBP, and T2D status) and relevant AA levels.
The OB-WC score was comprised of (in order of decreasing
association strength) asparagine, tyrosine, alanine, glycine,
valine, and glutamate, and the OB-BMI score of asparagine,
tyrosine, valine, alanine, isoleucine, and glycine. The levels
of both scores decreased after weight loss and weight mainte-
nance. However, while two individuals may have an equal
total AA association with obesity (i.e., equal OB scores), they
may beneﬁt diﬀerently from weight loss, since not all AAs
respond equally to treatment. Therefore, we removed AAs
that did not show long-term sustained change (towards levels
found in healthy subjects) from the OB scores and created the
WLWM-WC and WLWM-BMI scores deﬁning treatment-
modiﬁable association scores. Model predictions were calcu-
lated for both sets of scores. We found that for both the OB
and the WLWM scores, WC had a slightly higher prediction
value than BMI. Hypothetically, the weight loss and weight
maintenance scores could be used in evaluating the
treatment-speciﬁc likelihood of beneﬁt for an individual,
although this could not be validated in the replication cohort.
We observed that both WC and BMI scores decrease sub-
stantially in individuals with ≥10% weight loss due to favor-
able changed amino acid levels and potentially, systolic blood
pressure, while the scores increased in the <10% weight loss
group due to unchanged or unfavorable change of amino
acid levels and systolic blood pressure.
We also indirectly assessed the risk of future T2D [14]
and CVD [15] by evaluating the eﬀect of weight loss on the
DM-AA score. The DM-AA score decreased during weight
loss (both WLWM and replication cohort) and sustained
during weight maintenance, indicating that the risk for
T2D and CVD was reduced in the long-term by the weight
loss and weight maintenance program. In addition, an
increased risk was found in the group with <10% weight loss
(replication cohort). When analyzing the whole cohort, we
found a strong correlation between the change in BMI and
the corresponding change in DM-AA score after weight loss.
Since the DM-AA score, which consists of isoleucine, tyro-
sine, and phenylalanine, has been associated with insulin
resistance, T2D, and cardiovascular risk, decrease of an ele-
vated DM-AA score level may show decreased risk of devel-
oping these disorders [12, 14, 15, 19].
There are some limitations to this investigation that
should be recognized. The three cohorts analyzed were not
matched and the diﬀerences in, for example, age, gender dis-
tribution, and T2D, might aﬀect the generalizability of the
results. Even so, we want to highlight that the ﬁrst study
(MDC-CC) was used to ﬁnd AAs associated with WC and
BMI, which requires a larger cohort with a wider range of
BMI motivating the use of a population-based approach.
The weight loss and weight maintenance program was con-
ducted in a small group of subjects that has the beneﬁt of
being run in a supervised clinical trial setting targeting obese
individuals (separate from the MDC-CC); the replication
cohort was included to further evaluate the changes observed
after ≥10% weight loss as well as comparing results with sub-
jects with <10% weight loss. Furthermore, nutritional infor-
mation was considered neither in the WLWM nor in the
replication cohort other than that the participants reduced
their daily calorie intake, and nutritional content may inﬂu-
ence the results. To achieve the main goal of weight loss
and to maintain reduced weight, the overall calorie intake
was restricted and unhealthy eating habits were corrected
(with the help of a dietician and the behavioral change
program); diet composition was not accounted for.
In conclusion, we investigated the association between
circulating AA levels and abdominal or general obesity.
From a panel of 18 AAs, eight consistently showed associa-
tions with obesity. Out of these eight AAs, ﬁve changed as a
response to weight loss towards levels found in lean subjects
and one during weight maintenance, underlining the impor-
tance of more research on weight maintenance after weight
loss. The change of these six AAs was validated in a replica-
tion cohort. We developed scores based on WC or BMI
including sex, age, SBP, AHT, T2D status, and indepen-
dently associated AAs that describe the AA-associated bur-
den of obesity and found that each risk score decreased
with ≥10% weight loss. These scores may aid in the evalua-
tion on an individual level as to who will beneﬁt from
weight loss treatment in terms of cardiometabolic risk.
The concept of combining epidemiological data with
response to intervention may be implemented in other areas
of metabolic disease.
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